Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

A cost-of-illness study of spina bifida in Italy.

Colombo GL, Di Matteo S, Vinci M, Gatti C, Pascali MP, De Gennaro M, Macrellino E, Mosiello G, Redaelli T, Schioppa F, Dieci C.

Clinicoecon Outcomes Res. 2013 Jul 2;5:309-16. doi: 10.2147/CEOR.S42841. Print 2013.

2.

[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].

Llorca PM, Miadi-Fargier H, Lançon C, Jasso Mosqueda G, Casadebaig F, Philippe A, Guillon P, Mehnert A, Omnès LF, Chicoye A, Durand-Zaleski I.

Encephale. 2005 Mar-Apr;31(2):235-46. Review. French.

PMID:
15959450
3.

The social and economic burden of stroke survivors in Italy: a prospective, incidence-based, multi-centre cost of illness study.

Fattore G, Torbica A, Susi A, Giovanni A, Benelli G, Gozzo M, Toso V.

BMC Neurol. 2012 Nov 14;12:137. doi: 10.1186/1471-2377-12-137.

4.

Costs and quality of life of multiple sclerosis in Italy.

Kobelt G, Berg J, Lindgren P, Battaglia M, Lucioni C, Uccelli A.

Eur J Health Econ. 2006 Sep;7 Suppl 2:S45-54.

PMID:
17310336
5.

Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide in rheumatoid arthritis in Germany: I. Selected DMARDs and patient-related costs.

Schädlich PK, Zeidler H, Zink A, Gromnica-Ihle E, Schneider M, Straub C, Brecht JG, Huppertz E.

Pharmacoeconomics. 2005;23(4):377-93.

PMID:
15853437
6.
7.

Incidence of invasive cervical cancer and direct costs associated with its management in Italy.

Ricciardi A, Largeron N, Giorgi Rossi P, Raffaele M, Cohet C, Federici A, Palazzo F.

Tumori. 2009 Mar-Apr;95(2):146-52.

8.

Economic burden of bilateral neovascular age-related macular degeneration: multi-country observational study.

Cruess AF, Zlateva G, Xu X, Soubrane G, Pauleikhoff D, Lotery A, Mones J, Buggage R, Schaefer C, Knight T, Goss TF.

Pharmacoeconomics. 2008;26(1):57-73.

PMID:
18088159
9.

Association between visual acuity and medical and non-medical costs in patients with wet age-related macular degeneration in France, Germany and Italy.

Bandello F, Augustin A, Sahel JA, Benhaddi H, Negrini C, Hieke K, Berdeaux GH; MICMAC (MICro-economics of MACular degeneration) Study Group.

Drugs Aging. 2008;25(3):255-68.

PMID:
18331076
10.

Labor market productivity costs for caregivers of children with spina bifida: a population-based analysis.

Tilford JM, Grosse SD, Goodman AC, Li K.

Med Decis Making. 2009 Jan-Feb;29(1):23-32. doi: 10.1177/0272989X08322014. Epub 2008 Aug 25.

PMID:
18725406
11.

The Chikungunya epidemic on La Réunion Island in 2005-2006: a cost-of-illness study.

Soumahoro MK, Boelle PY, Gaüzere BA, Atsou K, Pelat C, Lambert B, La Ruche G, Gastellu-Etchegorry M, Renault P, Sarazin M, Yazdanpanah Y, Flahault A, Malvy D, Hanslik T.

PLoS Negl Trop Dis. 2011 Jun;5(6):e1197. doi: 10.1371/journal.pntd.0001197. Epub 2011 Jun 14.

13.

Costs and quality of life in multiple sclerosis in The Netherlands.

Kobelt G, Berg J, Lindgren P, Anten B, Ekman M, Jongen PJ, Polman C, Uitdehaag B.

Eur J Health Econ. 2006 Sep;7 Suppl 2:S55-64. Erratum in: Eur J Health Econ. 2007 Dec;8(4):359. Anten, Bert [added]; Ekman, Mattias [added]; Jongen, Peter J H [added]; Polman, Chris [added]; Uitdehaag, Bernard [added].

PMID:
17310343
14.

Methods for developing useful estimates of the costs associated with birth defects.

Case AP, Canfield MA.

Birth Defects Res A Clin Mol Teratol. 2009 Nov;85(11):920-4. doi: 10.1002/bdra.20637.

PMID:
19830852
15.

[Managing patients with prostate cancer in Italy during the first year after diagnosis. A cost description based on a sample of 8 urological wards].

Lazzaro C; Gruppo Informale di Studio sugli aspetti Economico-Sanitari del Carcinoma Prostatico in Italia.

Arch Ital Urol Androl. 2003 Sep;75(3):138-49. Italian.

PMID:
14661392
16.

Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia : a 12- and 24-month follow-up from the e-STAR database in Spain.

Olivares JM, Rodriguez-Martinez A, Burón JA, Alonso-Escolano D, Rodriguez-Morales A; e-STAR Study Group.

Appl Health Econ Health Policy. 2008;6(1):41-53.

PMID:
18774869
17.

Capecitabine versus bolus fluorouracil plus leucovorin (folinic acid) as adjuvant chemotherapy for patients with Dukes' C colon cancer : economic evaluation in an Italian NHS setting.

Di Costanzo F, Ravasio R, Sobrero A, Bertetto O, Vinante O, Luppi G, Labianca R, Amadori D, Barone C, Carlo Merlano M, Longo F, Mansueto G, Antonuzzo L, Gasperoni S.

Clin Drug Investig. 2008;28(10):645-55.

PMID:
18783303
18.

Cost of depression in Europe.

Sobocki P, Jönsson B, Angst J, Rehnberg C.

J Ment Health Policy Econ. 2006 Jun;9(2):87-98.

PMID:
17007486
19.

The cost of HIV disease in Northern Italy: the payer's perspective.

Rizzardini G, Restelli U, Bonfanti P, Porazzi E, Ricci E, Casartelli L, Foglia E, Carenzi L, Citterio P, Orlando G, Maselli C, Croce D.

J Acquir Immune Defic Syndr. 2011 Jul 1;57(3):211-7. doi: 10.1097/QAI.0b013e31821fdee2.

PMID:
21546850
20.

Evaluation of non-medical costs associated with visual impairment in four European countries: France, Italy, Germany and the UK.

Lafuma A, Brézin A, Lopatriello S, Hieke K, Hutchinson J, Mimaud V, Berdeaux G.

Pharmacoeconomics. 2006;24(2):193-205.

PMID:
16460138
Items per page

Supplemental Content

Write to the Help Desk